Search results
Showing 1 to 2 of 2 results for ta127
Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.
View recommendations for TA127Show all sections
Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]
Suggested remit: To appraise the clinical and cost effectiveness of natalizumab within its marketing authorisation for treating highly active relapsing-remittin...